2018 Volume 55 Issue 1 Pages 33-36
Temozolomide (TMZ) has recently been used for relapsed medulloblastoma; however, its use is limited in Japan. A 6-year-old boy with high-risk medulloblastoma in the cerebellum was treated by surgery, radiotherapy, and chemotherapy consisting of ifosfamide, cisplatin, and etoposide, followed by high-dose chemotherapy consisting of busulfan and melphalan and rescued by autologous stem cell transplantation. Twenty-four months after surgery, the medulloblastoma relapsed in the right lateral ventricle, temporal lobe, and left cerebellar hemisphere. Oral temozolomide [150 mg/m2 once daily for 5 days, repeated every 28 days (one cycle)] was started as a palliative therapy. To date, temozolomide has been repeated for 30 cycles for 28 months and the relapsed lesions have become smaller. The adverse effects of temozolomide on the patient were mild, and he was able to live with a good quality of life. Temozolomide is a good agent for medulloblastoma relapse.
